| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Commonly used anti–von Willebrand factor antibody for multimer analysis cross‐reacts with fibronectin, which is difficult to distinguish from von Willebrand factor
|
Eura, Yuka
|
|
|
5 |
6 |
p.
|
artikel
|
| 2 |
Convenience and satisfaction in direct oral anticoagulant–treated patients with atrial fibrillation
|
Piersma‐Wichers, Margriet
|
|
|
5 |
6 |
p.
|
artikel
|
| 3 |
Corticosteroid overuse in adults with immune thrombocytopenia: Cause for concern
|
Cuker, Adam
|
|
|
5 |
6 |
p.
|
artikel
|
| 4 |
Deterioration of vaccine‐induced immune thrombotic thrombocytopenia treated by heparin and platelet transfusion: Insight from functional cytometry and serotonin release assay
|
Bérezné, Alice
|
|
|
5 |
6 |
p.
|
artikel
|
| 5 |
Hemostasis and fibrinolysis in COVID‐19 survivors 6 months after intensive care unit discharge
|
Hulshof, Anne‐Marije
|
|
|
5 |
6 |
p.
|
artikel
|
| 6 |
Issue Information
|
|
|
|
5 |
6 |
p.
|
artikel
|
| 7 |
Low ADAMTS‐13 predicts adverse outcomes in hospitalized patients with suspected heparin‐induced thrombocytopenia
|
Chan, Meng
|
|
|
5 |
6 |
p.
|
artikel
|
| 8 |
Prevalence of thrombocytopenia, anti–platelet factor 4 antibodies and D‐dimer elevation in Thai people After ChAdOx1 nCoV‐19 vaccination
|
Uaprasert, Noppacharn
|
|
|
5 |
6 |
p.
|
artikel
|
| 9 |
Pseudohomozygous dysfibrinogenemia
|
Peck, Rachel C.
|
|
|
5 |
6 |
p.
|
artikel
|
| 10 |
Quantitative 3D microscopy highlights altered von Willebrand factor α‐granule storage in patients with von Willebrand disease with distinct pathogenic mechanisms
|
Swinkels, Maurice
|
|
|
5 |
6 |
p.
|
artikel
|
| 11 |
Response to rituximab in children and adults with immune thrombocytopenia (ITP)
|
Harris, Emily M.
|
|
|
5 |
6 |
p.
|
artikel
|
| 12 |
Severe COVID‐19 is associated with endothelial activation and abnormal glycosylation of von Willebrand factor in patients undergoing hemodialysis
|
Mobayen, Golzar
|
|
|
5 |
6 |
p.
|
artikel
|
| 13 |
Significant reduction in hemarthrosis in boys with severe hemophilia A: The China hemophilia individualized low‐dose secondary prophylaxis study
|
Wu, Runhui
|
|
|
5 |
6 |
p.
|
artikel
|
| 14 |
Subcutaneous engineered factor VIIa marzeptacog alfa (activated) in hemophilia with inhibitors: Phase 2 trial of pharmacokinetics, pharmacodynamics, efficacy, and safety
|
Mahlangu, Johnny
|
|
|
5 |
6 |
p.
|
artikel
|
| 15 |
The intersection of vector biology, gene therapy, and hemophilia
|
Lisowski, Leszek
|
|
|
5 |
6 |
p.
|
artikel
|
| 16 |
The use of qualitative methods in venous thromboembolism research
|
Hernandez‐Nino, Jackeline
|
|
|
5 |
6 |
p.
|
artikel
|
| 17 |
Thrombosis in myeloproliferative neoplasms: Treatment outcomes of direct oral anticoagulants and vitamin K antagonists
|
Fedorov, Kateryna
|
|
|
5 |
6 |
p.
|
artikel
|
| 18 |
Vaccine‐induced immune thrombotic thrombocytopenia following AstraZeneca (ChAdOx1 nCOV19) vaccine–A case report
|
Al Rawahi, Bader
|
|
|
5 |
6 |
p.
|
artikel
|
| 19 |
Vaccine‐induced immune thrombotic thrombocytopenia presenting with normal platelet count
|
Page, David
|
|
|
5 |
6 |
p.
|
artikel
|
| 20 |
Venous thrombosis recurrence risk according to warfarin versus direct oral anticoagulants for the secondary prevention of venous thrombosis
|
Zakai, Neil A.
|
|
|
5 |
6 |
p.
|
artikel
|
Tijdschrift beschrijving